Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Larimar Therapeutics, Inc. (LRMR)
Company Research
Source: GlobeNewswire
Open label extension (OLE) study is progressing with all 7 sites activated; interim data planned for Q4 2024Selected by Food and Drug Administration (FDA) to participate in Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program for nomlabofusp Joined TRACK-FA Neuroimaging Consortium as an industry partner; TRACK-FA collects natural history data to establish disease-specific neuroimaging biomarkers for potential use in clinical trialsPlanning initiation of pharmacokinetic (PK) run-in study in adolescents by year-end 2024; plan to transition adolescents into ongoing OLE study upon completion of PK studyPlanning initiation of global confirmatory study by mid-2025 with potential sites in the U.S., Europe, U.K., Canada, and AustraliaBiologics License Application (BLA) filing targeted for 2H 2025 to support accelerated approvalStrong balance sheet of $226.1 million cash, cash equivalents and marketable securities as of June 30, 2024, with projected cash runway
Show less
Read more
Impact Snapshot
Event Time:
LRMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LRMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LRMR alerts
High impacting Larimar Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LRMR
News
- Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia ResearchGlobeNewswire
- Larimar Therapeutics, Inc. (NASDAQ: LRMR) was upgraded by analysts at Baird R W to a "strong-buy" rating.MarketBeat
- Larimar Therapeutics, Inc. (NASDAQ: LRMR) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $16.00 price target on the stock.MarketBeat
- Larimar Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Bullish Larimar Therapeutics Insiders Loaded Up On US$540.7k Of Stock [Yahoo! Finance]Yahoo! Finance
LRMR
Earnings
- 8/7/24 - Miss
LRMR
Sec Filings
- 8/8/24 - Form 10-Q
- 8/7/24 - Form 8-K
- LRMR's page on the SEC website